Long-Term Protection and Antibody Levels 35 Years after Primary Immunization Series with Hepatitis B Vaccine and Response to a Booster Dose in Those Persons Who Lost Antibody

2021 ◽  
Author(s):  
Michael George Bruce ◽  
Dana Bruden ◽  
Debby Hurlburt ◽  
Julie Morris ◽  
Sara Bressler ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccine ◽  
Primary Immunization ◽  
Antibody Levels ◽  
Immunization Series

scholarly journals Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care students

2019 ◽  
Author(s):  
Behzad Bijani ◽  
Abbas Allami ◽  
Farzaneh Jafari ◽  
Fatemeh Hajmanoochehri ◽  
Soroush Bijani
Keyword(s):  
Health Care ◽  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccine ◽  
Health Care Students

Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis

Vaccine ◽  
2010 ◽  
Vol 28 (3) ◽  
pp. 623-631 ◽  
Author(s):  
Jalal Poorolajal ◽  
Mahmood Mahmoodi ◽  
Reza Majdzadeh ◽  
Siavosh Nasseri-Moghaddam ◽  
AliAkbar Haghdoost ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Meta Analysis ◽  
Hepatitis B Vaccine

scholarly journals Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ning Miao ◽  
Hui Zheng ◽  
Xiaojin Sun ◽  
Guomin Zhang ◽  
Fuzhen Wang
Keyword(s):  
Clinical Practice ◽  
Hepatitis B ◽  
Booster Dose ◽  
Information Management System ◽  
Hepatitis B Vaccine ◽  
Serological Response ◽  
Hbsag Positivity ◽  
Significant Difference ◽  
Expanded Program On Immunization ◽  
Antibody Levels

Abstract In 2002, China integrated hepatitis B vaccine (HepB) into its Expanded Program on Immunization (EPI) using HepB vaccine containing 5 µg of antigen. Although not recommended nationally, there was a common clinical practice in China of screening children for anti-HBs antibody level and giving a booster dose to HBV surface antigen (HBsAg)-negative children with non-protective anti-HBs antibody levels. We report an evaluation of the protective effectiveness of the 5 µg HepB vaccine and the serological response to the booster dose. We used data from a 2014 hepatitis B serological survey to determine HBsAg positivity and anti-HBs antibody levels among children who received and did not receive a booster dose. We determined HepB coverage from the Children Immunization Information Management System (CIIMS). We obtained and analyzed reports of acute Hepatitis B (AHB) during 2008–2014 obtained from the National Notifiable Disease Reporting System (NNDRS). The HBsAg-positive rate among children who had not received a booster dose was 0.41%, and did not increase with age (i.e., time since infant immunization). The anti-HBs positivity rate among the 6% of children who received a booster dose (88.41%) was higher than among those who had not received a booster (60.85%); anti-HBs antibody levels declined with age regardless of booster dose status. There was no statistically significant difference in HBsAg positivity between children who received a booster dose and those who did not. The AHB incidence among children born between 2002 and 2007 did not increase with age. Use of routine 5 µg HepB vaccine was not associated with an increase in AHB or of HBsAg positivity by time since vaccination, providing supportive evidence that individuals vaccinated with the 5 µg HepB vaccine do not need a booster dose. Although a booster dose was associated with increases in anti-HBs antibody levels, our study provided no evidence to support the need for this clinical practice. We should continue to strengthen serological monitoring of children, especially for those born to HBsAg positive mothers.

scholarly journals Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22‐Year Follow‐Up Study and Response to a Booster Dose

2009 ◽  
Vol 200 (9) ◽  
pp. 1390-1396 ◽  
Author(s):  
Brian J. McMahon ◽  
Catherine M. Dentinger ◽  
Dana Bruden ◽  
Carolyn Zanis ◽  
Helen Peters ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccine ◽  
Follow Up Study ◽  
Antibody Levels

scholarly journals Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

2016 ◽  
Vol 214 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Michael G. Bruce ◽  
Dana Bruden ◽  
Debby Hurlburt ◽  
Carolyn Zanis ◽  
Gail Thompson ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccine ◽  
Follow Up Study ◽  
Antibody Levels

Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine

Vaccine ◽  
2013 ◽  
Vol 31 (3) ◽  
pp. 448-451 ◽  
Author(s):  
Vladimir Gilca ◽  
Gaston De Serres ◽  
Nicole Boulianne ◽  
Donald Murphy ◽  
Philippe De Wals ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccine ◽  
Recombinant Hepatitis ◽  
Antibody Persistence

scholarly journals Long-term protection at 20–31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community

2019 ◽  
Vol 16 (1) ◽  
pp. 16-20
Author(s):  
Jing-Chen Ma ◽  
Zhi-Wei Wu ◽  
Hai-Song Zhou ◽  
Zhao Gao ◽  
Zhi-Yong Hao ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Rural Community ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine
Sign in / Sign up

Export Citation Format

Share Document